Business Context and Reporting Period
This Form 8-K, dated August 2, 2024, reports on the extraordinary general meeting of TenX Keane Acquisition (TenX), a Cayman Islands exempted company. The filing details the shareholder approval of a business combination with Citius Pharmaceuticals, Inc. (Citius), which will result in TenX domesticating as a Delaware corporation and changing its name to Citius Oncology, Inc. (New Citius Oncology).
Key Financial Metrics and Transaction Details
This filing is a current report regarding corporate governance and transaction approvals; it does not contain standard financial statements such as revenue, profit, or cash flow for a reporting period.
- Redemptions: Holders of 4,297,828 TenX Ordinary Shares exercised redemption rights.
- Redemption Price: Approximately $11.46 per share.
- Total Redemption Amount: $49,265,965.44 in aggregate.
- Stock Incentive Plan: Approved a plan to issue up to 15,000,000 shares of New Citius Oncology Common Stock, representing approximately 19.8% of fully-diluted shares outstanding under a Maximum Redemption Scenario.
Material Changes and Voting Results
Shareholders representing 84.25% of outstanding ordinary shares voted at the meeting. The following proposals were approved:
- Business Combination (Proposal 1): Approved with 5,094,515 votes For, 510,718 Against.
- Domestication and Name Change (Proposal 2): Approved to transfer from Cayman Islands to Delaware and rename to Citius Oncology, Inc. (4,561,114 For, 1,044,119 Against).
- Organizational Documents (Proposal 3): Approved amendments to the certificate of incorporation and bylaws.
- Governance Changes (Proposal 4): Approved changes including a classified board of directors, exclusive forum provisions for Delaware courts, and restrictions on written consent actions.
- Stock Issuance (Proposal 5): Approved issuance of shares pursuant to the merger and domestication.
- Director Elections (Proposal 7): Eight directors were elected to serve staggered terms (Classes I, II, and III).
Outlook, Risks, and Management Commentary
The filing confirms that the business combination is subject to closing conditions outlined in the Merger Agreement. The 2024 Omnibus Stock Incentive Plan will become effective upon the closing of the Business Combination. The filing notes that the company is an emerging growth company. No specific forward-looking financial guidance or risk factors beyond standard transaction contingencies are detailed in this specific 8-K text.
Investor Verification Checklist
- Verify the final closing date of the Business Combination and Domestication.
- Confirm the post-transaction share count and trading symbol for New Citius Oncology on Nasdaq.
- Review the definitive proxy statement/prospectus filed on July 12, 2024, for full details on the Merger Agreement and financial projections.
- Monitor the implementation of the 2024 Omnibus Stock Incentive Plan and potential dilution impact.
- Check for any remaining conditions precedent to the closing of the merger.